MedPath

A 12-week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of DKB-140 on Gingival Health

Not Applicable
Recruiting
Conditions
Not Applicable
Registration Number
KCT0009501
Lead Sponsor
Dong Kook Pharm
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
120
Inclusion Criteria

1)An adult over 19 years of age and under 80 years of age
2)A person who has at least one tooth with a BLEEDING ON PROBING (BOP) site of 10% or more and a PD (Probing Depth) of 3 mm or more and 5 mm or less in all site(excluding those requiring medication or prescription for use of medication, and those with some sites falling into the 5 mm category due to attachment loss or moderate periodontitis)
3)A person who has one or more site with a GI score of 2 or more
4)Those who have at least 20 natural teeth (excluding implants and third molars)
5)A person who agrees to participate in this human body application test before the start of the human body application test and prepares a written consent form

Exclusion Criteria

1)A person with clinically significant cardiovascular, immune, or infectious diseases
2)Mentally ill patients such as schizophrenia, depression, and drug addiction
3)A person who has developed cancer within the past five years
4)A person who has a history of bleeding or disease
5)A person who shows serious pathological findings in soft tissue in the oral cavity{Desquamative gingivitis symptoms resulting from unknown causes, hormonal changes, immune system abnormalities, nonspecific oral reactions to systemic diseases(eg.Flat lesions and bullous lesions), or oral manifestations such as oral cancer, oral leukoplakia, palatal rugae, fibromas, and giant cell tumors of soft tissues}
6)A person with five or more teeth requiring immediate dental caries treatment within the oral cavity
7)A person requiring surgical or extraction procedures due to concurrent orthodontic or dental diseases during the trial period
8)A person who have received scaling treatment within 3 months of Visit 1 or periodontal treatment within 6 months of Visit 1
9)A person who have taken medications affecting periodontal status {including Phenytoin, CCBs, Cyclosporine, Anticoagulants (e.g., Coumadin), NSAIDs, Antiplatelets (e.g., Aspirin)} for more than 5 consecutive days within 1 month of Visit 1
10)A person who have taken antibiotics or adjunctive periodontal treatment within 1 month of Visit 1
11)A person who have consumed oral health-related functional foods within 1 month of Visit 1
12)A person who have consumed herbal medicine, health functional foods, or dietary supplements for anti-inflammatory or antioxidant purposes within 1 week of Visit 1
13)Patients with uncontrolled hypertension (systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg, measured criteria after 10 minutes of rest for subjects undergoing human clinical trials)
14)Patients with uncontrolled diabetes (HbA1c > 7.0% or initiation of medication due to diabetes within 3 months of Visit 1, changes in dosage or medication currently being taken)
15)A person with Creatinine levels exceeding twice the upper limit of normal at the enrolling institution
16)A person with AST (GOT) or ALT (GPT) levels exceeding three times the upper limit of normal at the enrolling institution
17)Heavy smokers (=20 cigarettes/day)
18)Excessive alcohol consumers (men =40 g/day, women =20 g/day)
19)A person who have participated in another interventional clinical trial (including human clinical trials) within 3 months before Visit 1, or plan to participate in another interventional clinical trial (including human clinical trials) after the start of this human clinical trial
20)Pregnant or lactating women (including up to 6 months postpartum) or individuals planning pregnancy during the study period
21)A person sensitive or allergic to ingredients in the test food for this clinical trial
22)A person deemed inappropriate for participation by the investigator in this clinical trial

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath